Sample Page

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells.

To take part in the trial, patients must also have a particular tissue marker called HLA-A2, which is found through routine testing.

The trial will be carried out in two parts:

• Phase 1 will focus on finding the safest dose of brenetafusp, either on its own or in combination with other treatments such as chemotherapy, targeted therapy, or other immunotherapies.
• Phase 2 will explore how well brenetafusp works in shrinking or controlling selected types of advanced cancers.

This is the first time brenetafusp is being tested in humans, so the study will carefully monitor safety and side effects, as well as how the drug behaves in the body and its impact on the cancer.

This is an early-phase clinical trial testing a new drug called BI-1607 for people with melanoma that has spread or cannot be removed by surgery. The aim is to see whether combining BI-1607 with two existing treatments, ipilimumab and pembrolizumab, is safe and more effective than current options. BI-1607 is designed to help the body’s immune system work better by enhancing the effects of ipilimumab and pembrolizumab, two immunotherapies already used to treat melanoma.

Around 35 people are expected to take part in the study, all of whom have melanoma that hasn’t responded to standard treatments.The trial has two parts:

Phase 1: At least 15 participants will be given BI-1607 alongside ipilimumab every three weeks over a 12-week period. Pembrolizumab will be added during the later part of this phase. After the initial 12 weeks, participants who continue in the trial will receive pembrolizumab alone for up to two years. Different groups will receive different dose levels to help researchers find the safest and most effective combination.

Phase 2: Around 20 more participants will receive the dose combination found to be safest in Phase 1. They will follow a similar treatment schedule, beginning with BI-1607, ipilimumab, and pembrolizumab for 12 weeks, followed by pembrolizumab alone.

All treatments are given through a drip into a vein (IV infusion). Participants will be closely monitored throughout the trial, with regular blood tests, scans, and health checks. The lowest dose of BI-1607 will be 350 mg, and the highest will be 700 mg. Ipilimumab will be given at 1 or 3 mg per kilogram of body weight, and pembrolizumab at 200 mg.

The trial will also look at how the treatment affects the immune system and how well it controls the cancer. Researchers will monitor any side effects, including serious ones that could stop treatment.

While participants may not benefit personally, their involvement could help improve treatment for future melanoma patients.

The study began in late 2024 and is expected to run until 2028.

This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.

This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in the body (pharmacokinetics), and its ability to fight tumours.

The trial includes three stages: a dose escalation phase to find the optimal dose, a dose expansion phase to further test the treatment, and Phase 2A cohorts to assess its effectiveness in specific patient groups. Up to 200 patients will take part, and the study will be conducted at up to 15 sites across the United States.

This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity of Roginolisib.

This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a PARP inhibitor) or gemcitabine (a chemotherapy drug) to determine its potential in fighting tumours.

This is the first trial in humans to test T3P-Y058-739, a genetically modified and weakened strain of the bacterium Yersinia enterocolitica. The study aims to find the right dose, test its safety, and see how well it works in people with advanced solid tumours.

DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.

The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).